Document is current
Any future updates will be listed below
-
Authors
Wittemans, Laura B. L.
Lotta, Luca A.
Oliver-Williams, Clare
Stewart, Isobel D.
Surendran, Praveen
Karthikeyan, Savita
Day, Felix R. https://orcid.org/0000-0003-3789-7651
Koulman, Albert https://orcid.org/0000-0001-9998-051X
Imamura, Fumiaki https://orcid.org/0000-0002-6841-8396
Zeng, Lingyao
Erdmann, Jeanette
Schunkert, Heribert
Khaw, Kay-Tee
Griffin, Julian L.
Forouhi, Nita G. https://orcid.org/0000-0002-5041-248X
Scott, Robert A.
Wood, Angela M.
Burgess, Stephen https://orcid.org/0000-0001-5365-8760
Howson, Joanna M. M. https://orcid.org/0000-0001-7618-0050
Danesh, John
Wareham, Nicholas J.
Butterworth, Adam S. https://orcid.org/0000-0002-6915-9015
Langenberg, Claudia https://orcid.org/0000-0002-5017-7344
- License Information
-
More Information
Article History
Received: 7 July 2018
Accepted: 11 February 2019
First Online: 5 March 2019
Competing interests
: R.A.S. is an employee and shareholder of GlaxoSmithKline. C.O.-W. received prize money from Novartis (<£1000). J.D. reports grants and personal fees from Merck Sharp & Dohme (MSD), grants and personal fees from Novartis, grants from British Heart Foundation, grants from European Research Council, grants from NIHR, grants from NHS Blood and Transplant, grants from Pfizer, grants from UK MRC, grants from Wellcome Trust, grants from AstraZeneca, outside the submitted work. J.D. also reports non-financial support from Merck Sharp & Dohme (MSD) and non-financial support from Novartis, outside the submitted work. A.B. has received grants outside of this work from AstraZeneca, Biogen, Merck, Novartis and Pfizer and personal fees outside of this work from Novartis. The remaining authors declare no competing interests.
